BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7296550)

  • 1. Pharmacokinetics of vincristine infusion.
    Jackson DV; Sethi VS; Spurr CL; White DR; Richards F; Stuart JJ; Muss HB; Cooper MR; Castle MC
    Cancer Treat Rep; 1981; 65(11-12):1043-8. PubMed ID: 7296550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of vincristine in the cerebrospinal fluid of humans.
    Jackson DV; Sethi VS; Spurr CL; McWhorter JM
    Cancer Res; 1981 Apr; 41(4):1466-8. PubMed ID: 6260340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients.
    Bedikian AY; Vardeleon A; Smith T; Campbell S; Namdari R
    J Clin Pharmacol; 2006 Jul; 46(7):727-37. PubMed ID: 16809798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vincristine by continuous infusion in refractory breast cancer: a phase II study.
    Hopkins JO; Jackson DV; White DR; Muss HB; Richards F; Cooper MR; Stuart JJ; Sparr CL; Wells HB
    Am J Clin Oncol; 1983 Oct; 6(5):529-32. PubMed ID: 6613919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing the dosage of vincristine: a clinical and pharmacokinetic study of continuous-infusion vincristine in children with central nervous system tumors.
    Kellie SJ; Koopmans P; Earl J; Nath C; Roebuck D; Uges DR; De Graaf SS
    Cancer; 2004 Jun; 100(12):2637-43. PubMed ID: 15197807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous vincristine infusion: phase I trial.
    Jackson DV; Sethi VS; Spurr CL; Willard V; White DR; Richards F; Stuart JJ; Muss HB; Cooper MR; Homesley HD; Jobson VW; Castle MC
    Cancer; 1981 Dec; 48(12):2559-64. PubMed ID: 7306914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of vincristine sulfate in adult cancer patients.
    Sethi VS; Jackson DV; White DR; Richards F; Stuart JJ; Muss HB; Cooper MR; Spurr CL
    Cancer Res; 1981 Sep; 41(9 Pt 1):3551-5. PubMed ID: 7260915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase Ib trial of bryostatin 1 in patients with refractory malignancies.
    Grant S; Roberts J; Poplin E; Tombes MB; Kyle B; Welch D; Carr M; Bear HD
    Clin Cancer Res; 1998 Mar; 4(3):611-8. PubMed ID: 9533528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
    Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia.
    Thomas DA; Sarris AH; Cortes J; Faderl S; O'Brien S; Giles FJ; Garcia-Manero G; Rodriguez MA; Cabanillas F; Kantarjian H
    Cancer; 2006 Jan; 106(1):120-7. PubMed ID: 16331634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection.
    Embree L; Gelmon K; Tolcher A; Hudon N; Heggie J; Dedhar C; Logan P; Bally MB; Mayer LD
    Cancer Chemother Pharmacol; 1998; 41(5):347-52. PubMed ID: 9523729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies.
    Dowlati A; Lazarus HM; Hartman P; Jacobberger JW; Whitacre C; Gerson SL; Ksenich P; Cooper BW; Frisa PS; Gottlieb M; Murgo AJ; Remick SC
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5929-35. PubMed ID: 14676117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    Varterasian ML; Mohammad RM; Shurafa MS; Hulburd K; Pemberton PA; Rodriguez DH; Spadoni V; Eilender DS; Murgo A; Wall N; Dan M; Al-Katib AM
    Clin Cancer Res; 2000 Mar; 6(3):825-8. PubMed ID: 10741703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [EPOCH therapy for relapsed/refractory lymphoid malignancies].
    Dobashi N; Usui N; Kobayashi T; Yamazaki H; Asai O; Yano S; Kato A; Watanabe H; Nagamine M; Katori M; Tajima N; Kuraishi Y
    Rinsho Ketsueki; 1998 Apr; 39(4):267-72. PubMed ID: 9597893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.
    Zylber-Katz E; Gomori JM; Schwartz A; Lossos A; Bokstein F; Siegal T
    Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of vindesine bolus and infusion.
    Jackson DV; Sethi VS; Long TR; Muss HB; Spurr CL
    Cancer Chemother Pharmacol; 1984; 13(2):114-9. PubMed ID: 6467494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Greater immediate gastric acid suppression with lansoprazole 30 mg administered as a 2-minute intravenous bolus injection versus a 30-minute infusion.
    Metz DC; Devlin JW; Vakily M; Atkinson S; Lloyd E
    Pharmacotherapy; 2008 Mar; 28(3):301-7. PubMed ID: 18294109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
    Licata G; Di Pasquale P; Parrinello G; Cardinale A; Scandurra A; Follone G; Argano C; Tuttolomondo A; Paterna S
    Am Heart J; 2003 Mar; 145(3):459-66. PubMed ID: 12660669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.
    Morgan RJ; Newman EM; Doroshow JH; McGonigle K; Margolin K; Raschko J; Chow W; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Carroll M; Vasilev S; Akman S; Coluzzi P; Wagman L; Longmate J; Paz B; Yen Y; Klevecz R
    Cancer Res; 1998 Jul; 58(13):2793-800. PubMed ID: 9661893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.
    Roboz GJ; Giles FJ; Ritchie EK; Allen-Bard S; Curcio TJ; Wilkes MA; Park SL; Kantarjian HM; Faderl S; Ravandi F; Kelner MJ; Feldman EJ
    J Clin Oncol; 2007 Jan; 25(1):10-5. PubMed ID: 17146106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.